Valuation : Quest PharmaTech Inc.

Market Cap 3.38M 2.44M 2.1M 1.97M 1.8M 232M 3.41M 23.37M 9.09M 118M 9.16M 8.96M 390M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 4.37M 3.15M 2.71M 2.55M 2.33M 300M 4.4M 30.18M 11.74M 152M 11.83M 11.57M 503M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
3 months-33.33%
6 months-33.33%
Current year-42.86%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.07
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 A OtherCompany 0 0% -
10/21/25 A Other

Chief Executive Officer

1,000,000 0.5913%
10/21/25 A Other

Chief Executive Officer

300,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-50.00%-71.43% 2.43M
-1.23%-1.91%+0.98%+17.94% 50.47B
-1.11%-2.84%+420.04%+505.15% 44.56B
-0.21%+0.37%+42.15%+17.32% 43.08B
-1.95%-3.33%+8.29%+73.25% 41.7B
-0.94%-1.77%+18.34%+46.84% 33.21B
-1.11%-4.20%+25.49%+119.78% 16.77B
+6.10%+4.40% - - 16.28B
+0.25%-0.41%+11.91%+29.03% 14.58B
-1.12%-3.46%+78.75%+39.37% 13.92B
Average -0.12%-1.11%+61.77%+86.36% 27.46B
Weighted average by Cap. -0.57%-1.05%+89.95%+122.92%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.3M -1.12M -1.05M -959K -124M -1.81M -12.45M -4.84M -62.68M -4.88M -4.77M -208M 5M 3.61M 3.1M 2.91M 2.66M 343M 5.03M 34.54M 13.44M 174M 13.54M 13.24M 576M
Net Debt 795K 573K 494K 464K 423K 54.56M 801K 5.49M 2.14M 27.66M 2.15M 2.11M 91.6M 986K 711K 612K 575K 525K 67.65M 993K 6.81M 2.65M 34.3M 2.67M 2.61M 114M
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume